CLSK Cleanspark | $14.54 +21.1% | 7/28/2026 | | Boost Price Target | $19.00 ➝ $21.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 7/28/2026 |
PMN Promis Neurosciences | $14.92 +6.1% | 7/27/2026 | | Set Price Target | $20.00 | Buy | 00.00% | View details for Chardan Capital rating of Promis Neurosciences (NASDAQ:PMN) on 7/27/2026 |
HIVE HIVE Digital Technologies | $3.00 +18.1% | 7/27/2026 | | Initiated Coverage | $7.50 | Buy | 00.00% | View details for Chardan Capital rating of HIVE Digital Technologies (NASDAQ:HIVE) on 7/27/2026 |
CIFR Cipher Mining | $22.66 +28.1% | 7/27/2026 | | Initiated Coverage | $32.00 | Buy | 00.00% | View details for Chardan Capital rating of Cipher Mining (NASDAQ:CIFR) on 7/27/2026 |
WULF TeraWulf | $17.82 +18.1% | 7/27/2026 | | Initiated Coverage | $32.00 | Buy | 00.00% | View details for Chardan Capital rating of TeraWulf (NASDAQ:WULF) on 7/27/2026 |
CIFR Cipher Mining | $22.66 +28.1% | 7/27/2026 | | Initiated Coverage | $32.00 | Buy | 00.00% | View details for Chardan Capital rating of Cipher Mining (NASDAQ:CIFR) on 7/27/2026 |
HIVE HIVE Digital Technologies | $3.00 +18.1% | 7/27/2026 | | Initiated Coverage | $7.50 | Buy | 00.00% | View details for Chardan Capital rating of HIVE Digital Technologies (NASDAQ:HIVE) on 7/27/2026 |
PMN Promis Neurosciences | $14.92 +6.1% | 7/27/2026 | | Initiated Coverage | $20.00 | Buy | 00.00% | View details for Chardan Capital rating of Promis Neurosciences (NASDAQ:PMN) on 7/27/2026 |
WULF TeraWulf | $17.82 +18.1% | 7/27/2026 | | Initiated Coverage | $32.00 | Buy | 00.00% | View details for Chardan Capital rating of TeraWulf (NASDAQ:WULF) on 7/27/2026 |
ARWR Arrowhead Pharmaceuticals | $87.32 +1.3% | 7/22/2026 | | Boost Price Target | $90.00 ➝ $115.00 | Buy | 00.00% | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 7/22/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
CLSK Cleanspark | $14.54 +21.1% | 7/15/2026 | | Reiterated Rating | $19.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 7/15/2026 |
CLSK Cleanspark | $14.54 +21.1% | 7/8/2026 | | Reiterated Rating | $19.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 7/8/2026 |
MGX Metagenomi | $1.22 +0.8% | 7/7/2026 | | Initiated Coverage | $7.00 ➝ $5.00 | Buy | 00.00% | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 7/7/2026 |
IRD Opus Genetics | $3.84 +10.7% | 7/6/2026 | | Reiterated Rating | $13.00 | Buy | 00.00% | View details for Chardan Capital rating of Opus Genetics (NASDAQ:IRD) on 7/6/2026 |
IBIO iBio | $1.39 +2.2% | 7/2/2026 | | Reiterated Rating | $5.00 | Buy | 00.00% | View details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 7/2/2026 |
TENX Tenax Therapeutics | $15.10 +1.9% | 7/2/2026 | | Reiterated Rating | $27.00 | Buy | 00.00% | View details for Chardan Capital rating of Tenax Therapeutics (NASDAQ:TENX) on 7/2/2026 |
EYPT Eyepoint Pharmaceuticals | $12.86 +7.9% | 7/1/2026 | | Boost Price Target | $29.00 ➝ $65.00 | Buy | 00.00% | View details for Chardan Capital rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 7/1/2026 |
ARWR Arrowhead Pharmaceuticals | $87.32 +1.3% | 6/30/2026 | | Reiterated Rating | $90.00 | Buy | 00.00% | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/30/2026 |
PRQR ProQR Therapeutics | $1.78 +2.9% | 6/26/2026 | | Lower Price Target | $4.00 ➝ $3.00 | Buy | 00.00% | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 6/26/2026 |
OCUL Ocular Therapeutix | $8.47 +1.3% | 6/25/2026 | | Boost Price Target | $21.00 ➝ $23.00 | Buy | 00.00% | View details for Chardan Capital rating of Ocular Therapeutix (NASDAQ:OCUL) on 6/25/2026 |
TENX Tenax Therapeutics | $15.10 +1.9% | 6/22/2026 | | Initiated Coverage | $27.00 | Buy | 00.00% | View details for Chardan Capital rating of Tenax Therapeutics (NASDAQ:TENX) on 6/22/2026 |
IRD Opus Genetics | $3.84 +10.7% | 6/18/2026 | | Boost Price Target | $11.00 ➝ $13.00 | Buy | 00.00% | View details for Chardan Capital rating of Opus Genetics (NASDAQ:IRD) on 6/18/2026 |
IRD Opus Genetics | $3.84 +10.7% | 6/17/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Chardan Capital rating of Opus Genetics (NASDAQ:IRD) on 6/17/2026 |
SABS SAB Biotherapeutics | $3.56 +2.3% | 6/17/2026 | | Boost Price Target | $14.00 ➝ $16.00 | Buy | 00.00% | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/17/2026 |
COYA Coya Therapeutics | $4.08 +5.4% | 6/12/2026 | | Reiterated Rating | $14.00 | Buy | 00.00% | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 6/12/2026 |
PURR Hyperliquid Strategies | $6.30 +5.5% | 6/12/2026 | | Reiterated Rating | $9.75 | Buy | 00.00% | View details for Chardan Capital rating of Hyperliquid Strategies (NASDAQ:PURR) on 6/12/2026 |
ZOOZ ZOOZ Power | $5.19 +2.4% | 6/12/2026 | | Lower Price Target | $40.00 ➝ $10.00 | Buy | 00.00% | View details for Chardan Capital rating of ZOOZ Power (NASDAQ:ZOOZ) on 6/12/2026 |
CAMP CAMP4 Therapeutics | $3.47 +6.1% | 6/10/2026 | | Set Price Target | $6.50 | Buy | 00.00% | View details for Chardan Capital rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 6/10/2026 |
CAMP CAMP4 Therapeutics | $3.47 +6.1% | 6/10/2026 | | Initiated Coverage | $6.50 | Buy | 00.00% | View details for Chardan Capital rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 6/10/2026 |
PHMMF Pharma Mar | $86.09
| 6/9/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Chardan Capital rating of Pharma Mar (OTCMKTS:PHMMF) on 6/9/2026 |
VFS VinFast Auto | $3.10 +3.3% | 6/9/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 6/9/2026 |
CLSK Cleanspark | $14.54 +21.1% | 6/8/2026 | | Boost Price Target | $16.00 ➝ $19.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 6/8/2026 |
HYPD Hyperion DeFi | $2.66 +13.7% | 6/8/2026 | | Lower Price Target | $8.25 ➝ $7.30 | Buy | 00.00% | View details for Chardan Capital rating of Hyperion DeFi (NASDAQ:HYPD) on 6/8/2026 |
KEEL Keel Infrastructure | $4.05 +27.4% | 6/8/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 6/8/2026 |
PVLA Palvella Therapeutics | $150.19 +5.3% | 5/21/2026 | | Reiterated Rating | $240.00 | Buy | 00.00% | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 5/21/2026 |
PURR Hyperliquid Strategies | $6.30 +5.5% | 5/20/2026 | | Boost Price Target | $8.45 ➝ $9.75 | Buy | 00.00% | View details for Chardan Capital rating of Hyperliquid Strategies (NASDAQ:PURR) on 5/20/2026 |
ALMS Alumis | $28.95 +9.7% | 5/19/2026 | | Boost Price Target | $38.00 ➝ $40.00 | Buy | 00.00% | View details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 5/19/2026 |
IMRX Immuneering | $4.23 +4.4% | 5/19/2026 | | Reiterated Rating | $20.00 | Buy | 00.00% | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 5/19/2026 |
IMTX Immatics | $9.20 +2.3% | 5/19/2026 | | Reiterated Rating | $25.00 | Buy | 00.00% | View details for Chardan Capital rating of Immatics (NASDAQ:IMTX) on 5/19/2026 |
SNTI Senti Biosciences | $0.36 +3.9% | 5/15/2026 | | Boost Price Target | $11.00 ➝ $12.00 | Buy | 00.00% | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 5/15/2026 |
CODE RED: AI Meltdown Imminent? (Ad) After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. See the five simple steps to prepare before it's too late |
KEEL Keel Infrastructure | $4.05 +27.4% | 5/11/2026 | | Reiterated Rating | $4.50 | Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 5/11/2026 |
KOD Kodiak Sciences | $42.50 +6.2% | 5/11/2026 | | Upgrade | $14.00 ➝ $61.00 | Neutral ➝ Buy | 00.00% | View details for Chardan Capital rating of Kodiak Sciences (NASDAQ:KOD) on 5/11/2026 |
LXEO Lexeo Therapeutics | $4.35 +0.9% | 5/11/2026 | | Reiterated Rating | $17.00 | Buy | 00.00% | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 5/11/2026 |
RCKT Rocket Pharmaceuticals | $3.21 +2.2% | 5/11/2026 | | Reiterated Rating | $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/11/2026 |
KDK Kodiak AI | $4.22 +4.9% | 5/8/2026 | | Lower Price Target | $22.00 ➝ $15.00 | Buy | 00.00% | View details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 5/8/2026 |
IOVA Iovance Biotherapeutics | $4.69 +2.9% | 5/7/2026 | | Lower Price Target | $16.00 ➝ $14.00 | Buy | 00.00% | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/7/2026 |
CLYM Climb Bio | $12.17 +0.5% | 5/5/2026 | | Initiated Coverage | $22.00 | Buy | 00.00% | View details for Chardan Capital rating of Climb Bio (NASDAQ:CLYM) on 5/5/2026 |
EDIT Editas Medicine | $2.69 +3.5% | 5/5/2026 | | Boost Price Target | $3.50 ➝ $4.00 | Buy | 00.00% | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 5/5/2026 |
GLXY Galaxy Digital | $21.52 +17.9% | 5/4/2026 | | Reiterated Rating | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of Galaxy Digital (NASDAQ:GLXY) on 5/4/2026 |
KEEL Keel Infrastructure | $4.05 +27.4% | 5/4/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 5/4/2026 |
RIOT Riot Platforms | $22.12 +21.3% | 5/4/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Chardan Capital rating of Riot Platforms (NASDAQ:RIOT) on 5/4/2026 |
QURE uniQure | $42.19 +5.3% | 4/30/2026 | | Boost Price Target | $31.00 ➝ $37.00 | Buy | 00.00% | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 4/30/2026 |
RIOT Riot Platforms | $22.12 +21.3% | 4/27/2026 | | Initiated Coverage | $27.50 | Buy | 00.00% | View details for Chardan Capital rating of Riot Platforms (NASDAQ:RIOT) on 4/27/2026 |
GLXY Galaxy Digital | $21.52 +17.9% | 4/27/2026 | | Initiated Coverage | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of Galaxy Digital (NASDAQ:GLXY) on 4/27/2026 |
KEEL Keel Infrastructure | $4.05 +27.4% | 4/27/2026 | | Initiated Coverage | $4.50 | Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 4/27/2026 |
NTLA Intellia Therapeutics | $11.09 +2.7% | 4/27/2026 | | Boost Price Target | $27.00 ➝ $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026 |
VFS VinFast Auto | $3.10 +3.3% | 4/23/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 4/23/2026 |
ANRO Alto Neuroscience | $28.61 +7.1% | 4/22/2026 | | Reiterated Rating | $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 4/22/2026 |
PASG Passage Bio | $4.49 -0.7% | 4/21/2026 | | Set Price Target | $21.00 ➝ $7.00 | Buy ➝ Neutral | 00.00% | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 4/21/2026 |
PASG Passage Bio | $4.49 -0.7% | 4/21/2026 | | Downgrade | $21.00 ➝ $7.00 | Buy ➝ Hold | 00.00% | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 4/21/2026 |
IOVA Iovance Biotherapeutics | $4.69 +2.9% | 4/10/2026 | | Reiterated Rating | $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 4/10/2026 |
IBIO iBio | $1.39 +2.2% | 4/9/2026 | | Reiterated Rating | $5.00 | Buy | 00.00% | View details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 4/9/2026 |
PRQR ProQR Therapeutics | $1.78 +2.9% | 4/9/2026 | | Reiterated Rating | $4.00 | Buy | 00.00% | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 4/9/2026 |
CLSK Cleanspark | $14.54 +21.1% | 4/8/2026 | | Reiterated Rating | $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 4/8/2026 |
ANRO Alto Neuroscience | $28.61 +7.1% | 4/2/2026 | | Reiterated Rating | $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 4/2/2026 |
PVLA Palvella Therapeutics | $150.19 +5.3% | 3/31/2026 | | Boost Price Target | $210.00 ➝ $240.00 | Buy | 00.00% | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 3/31/2026 |
ALMS Alumis | $28.95 +9.7% | 3/30/2026 | | Reiterated Rating | $38.00 | Buy | 00.00% | View details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 3/30/2026 |
MNPR Monopar Therapeutics | $114.66 +6.7% | 3/30/2026 | | Reiterated Rating | $100.00 | Buy | 00.00% | View details for Chardan Capital rating of Monopar Therapeutics (NASDAQ:MNPR) on 3/30/2026 |
SNTI Senti Biosciences | $0.36 +3.9% | 3/30/2026 | | Lower Price Target | $13.00 ➝ $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 3/30/2026 |
ZOOZ ZOOZ Power | $5.19 +2.4% | 3/30/2026 | | Reiterated Rating | $40.00 | Buy | 00.00% | View details for Chardan Capital rating of ZOOZ Power (NASDAQ:ZOOZ) on 3/30/2026 |
CGTX Cognition Therapeutics | $0.92 +1.7% | 3/27/2026 | | Reiterated Rating | $4.00 | Buy | 00.00% | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 3/27/2026 |
MGTX MeiraGTx | $11.98 +3.1% | 3/27/2026 | | Reiterated Rating | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 3/27/2026 |
RCKT Rocket Pharmaceuticals | $3.21 +2.2% | 3/27/2026 | | Reiterated Rating | $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 3/27/2026 |
ALNY Alnylam Pharmaceuticals | $205.48 -28.3% | 3/25/2026 | | Reiterated Rating | $425.00 | Buy | 00.00% | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 3/25/2026 |
KDK Kodiak AI | $4.22 +4.9% | 3/25/2026 | | Reiterated Rating | $22.00 | Buy | 00.00% | View details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 3/25/2026 |
OCGN Ocugen | $1.26 +5.9% | 3/25/2026 | | Reiterated Rating | $7.00 | Buy | 00.00% | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/25/2026 |
ZURA Zura Bio | $5.54 +4.3% | 3/23/2026 | | Boost Price Target | $10.00 ➝ $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 3/23/2026 |
ALMS Alumis | $28.95 +9.7% | 3/20/2026 | | Boost Price Target | $37.00 ➝ $38.00 | Buy | 00.00% | View details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 3/20/2026 |
ANNX Annexon | $5.27 +8.4% | 3/20/2026 | | Reiterated Rating | $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Annexon (NASDAQ:ANNX) on 3/20/2026 |
SLDB Solid Biosciences | $8.49 +5.6% | 3/20/2026 | | Reiterated Rating | $15.00 | Buy | 00.00% | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/20/2026 |
FDMT 4D Molecular Therapeutics | $10.07 +4.8% | 3/19/2026 | | Reiterated Rating | $26.00 | Buy | 00.00% | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 3/19/2026 |
TSHA Taysha Gene Therapies | $5.88 +4.8% | 3/19/2026 | | Reiterated Rating | $12.00 | Buy | 00.00% | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 3/19/2026 |
CRVO CervoMed | $2.52 +1.6% | 3/18/2026 | | Boost Price Target | $15.00 ➝ $21.00 | Buy | 00.00% | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/18/2026 |
IBIO iBio | $1.39 +2.2% | 3/18/2026 | | Reiterated Rating | $5.00 | Buy | 00.00% | View details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 3/18/2026 |
STOK Stoke Therapeutics | $30.04 +1.9% | 3/18/2026 | | Reiterated Rating | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 3/18/2026 |
ANRO Alto Neuroscience | $28.61 +7.1% | 3/17/2026 | | Reiterated Rating | $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 3/17/2026 |
ULYX Urgent.ly | $5.50
| 3/17/2026 | | Downgrade | $15.00 ➝ $5.50 | Buy ➝ Hold | 00.00% | View details for Chardan Capital rating of Urgent.ly (OTCMKTS:ULYX) on 3/17/2026 |
VFS VinFast Auto | $3.10 +3.3% | 3/17/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 3/17/2026 |
COYA Coya Therapeutics | $4.08 +5.4% | 3/16/2026 | | Reiterated Rating | $14.00 | Buy | 00.00% | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/16/2026 |
PVLA Palvella Therapeutics | $150.19 +5.3% | 3/16/2026 | | Reiterated Rating | $210.00 | Buy | 00.00% | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 3/16/2026 |
The dollar reset no one told you about (Ad) Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth.
Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. Read the full briefing and see how to position yourself now |
IRD Opus Genetics | $3.84 +10.7% | 3/12/2026 | | Boost Price Target | $9.00 ➝ $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Opus Genetics (NASDAQ:IRD) on 3/12/2026 |
OBIO Orchestra BioMed | $3.99 +5.0% | 3/12/2026 | | Reiterated Rating | $20.00 | Buy | 00.00% | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/12/2026 |
SLDB Solid Biosciences | $8.49 +5.6% | 3/12/2026 | | Reiterated Rating | $15.00 | Buy | 00.00% | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/12/2026 |
TNYA Tenaya Therapeutics | $0.75 +2.0% | 3/12/2026 | | Reiterated Rating | $8.00 | Buy | 00.00% | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/12/2026 |
KDK Kodiak AI | $4.22 +4.9% | 3/11/2026 | | Reiterated Rating | $22.00 | Buy | 00.00% | View details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 3/11/2026 |
SABS SAB Biotherapeutics | $3.56 +2.3% | 3/11/2026 | | Boost Price Target | $12.00 ➝ $14.00 | Buy | 00.00% | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 3/11/2026 |
DYN Dyne Therapeutics | $25.73 +2.5% | 3/9/2026 | | Reiterated Rating | $38.00 | Buy | 00.00% | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/9/2026 |
EDIT Editas Medicine | $2.69 +3.5% | 3/9/2026 | | Reiterated Rating | $3.50 | Buy | 00.00% | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 3/9/2026 |
QURE uniQure | $42.19 +5.3% | 3/9/2026 | | Boost Price Target | $16.00 ➝ $31.00 | Buy | 00.00% | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 3/9/2026 |
CRVO CervoMed | $2.52 +1.6% | 3/5/2026 | | Reiterated Rating | $15.00 | Buy | 00.00% | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/5/2026 |